H.C. Wainwright reiterates Ionis stock rating on hepatitis B data

H.C. Wainwright reiterated a Buy rating and $125 price target on Ionis Pharmaceuticals, implying about 63% upside from the current $76.50 share price. The key driver is positive Phase 3 data for partner GSK’s bepirovirsen, which posted a 19% functional cure rate in the broader chronic hepatitis B group and 26% in the lower-HBsAg subgroup versus 0% on standard of care. Ionis also reported Q1 2026 EPS of -$0.56 versus -$0.85 expected, revenue of $246 million versus $199.24 million expected, and raised full-year 2026 revenue guidance to $875 million-$900 million from $800 million-$825 million.

Analysis

IONS is increasingly behaving like a royalty compounder rather than a single-asset biotech, and that changes how the market should value it: less binary than traditional launch-stage names, but more sensitive to whether each partnered program de-risks a future stream. The bepirovirsen update matters most because it validates Ionis’ capital-light model at a time when the company is trying to re-rate from “pipeline optionality” to “durable cash-flow platform.” That supports a higher multiple, but the move can overextend if investors start capitalizing peak-sales headlines before the market actually sees reimbursement, labeling breadth, and real-world durability.

The second-order winner may be GSK, which gets a credible chronic-disease franchise in a space where functional cure claims can justify premium pricing and lifecycle expansion. But the bigger market implication is competitive pressure on the broader HBV ecosystem: a positive regulatory path for a royalty-backed therapy raises the bar for smaller HBV developers that rely on cleaner efficacy deltas to attract capital. If uptake is strongest in the low-HBsAg subgroup, commercial success could be narrower than the headline suggests, which would cap the revenue slope even with a favorable label.

The consensus appears to be underestimating timing risk. The PDUFA window is long enough for sentiment to swing on manufacturing, advisory committee dynamics, or rival clinical readouts; over the next 6-12 months, the stock will likely trade more on periodic catalysts than on terminal peak-sales math. The key contrarian point is that the stock may already be discounting a lot of the good news: after a large run, incremental upside probably needs either a higher-than-guided royalty contribution or a broader rerating of Ionis’ entire partnered portfolio, not just one approval.

Key Decisions for Investors

• Add IONS on pullbacks rather than strength; best entry is a 3-5% post-rally retracement, targeting a 12-18% upside move into the next catalyst window with downside limited if the royalty narrative stays intact.
• Sell upside calls on IONS against core long exposure into the October 2026 regulatory window to monetize elevated implied volatility; this is attractive if the stock begins pricing in peak-sales optimism faster than fundamentals.
• Pair trade: long IONS / short a lower-quality, single-asset biotech with near-term binary risk; the spread should benefit if the market keeps rewarding capital-light royalty models over cash-burning launch stories.
• If you want event-driven exposure, buy GSK calls or a call spread into the next HBV regulatory milestone; reward is best if the market starts assigning franchise value rather than treating bepirovirsen as an isolated asset.
• For a contrarian hedge, trim or short IONS on any move that forces the stock well above the highest analyst targets before approval; risk/reward worsens sharply once the market is capitalizing 2027+ royalties too aggressively.